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Abstract: The impact of highly active antiretroviral therapy (HAART) in the natural history of AIDS disease has been al-
lowed to prolong the survival of people with HIV infection, particularly whose with increased HIV viral load. Addition-
ally, the antiretroviral therapy could exert a certain degree of protection against parasitic diseases. A number of studies 
have been evidenced a decrease in the incidence of opportunistic parasitic infections in the era of HAART. Although these 
changes have been attributed to the restoration of cell-mediated immunity, induced by either non-nucleoside reverse tran-
scriptase inhibitors or HIV protease inhibitors, in combination with at least two nucleoside reverse transcriptase inhibitors 
included in HAART, there are evidence that the control of these parasitic infections in HIV-positive persons under 
HAART, is also induced by the inhibition of the proteases of the parasites. This review focuses on the principal available 
data related with therapeutic HIV-protease inhibitors and their in vitro and in vivo effects on the opportunistic protozoan 
parasites. 
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1. INTRODUCTION 
  Since the introduction of highly active antiretroviral ther-
apy (HAART) the mortality and morbidity for a wide variety 
of opportunistic viral, bacterial, fungal and parasitic infec-
tions have decreased dramatically among HIV-infected indi-
viduals in economically developed countries [1].  
  In a multinational cohort study involving 6941 individu-
als with the human immunodeficiency virus (HIV) from 
Australia and ten European countries, when comparing the 
periods 1997-2001 and 1994-1996, there was a significant 
HAART-induced decreases (e.g. candiadiasis from 17.0% to 
5.7%; cryptosporidiosis from 3.1% to 0.2%; cytomegalovi-
rosis from 5.9% to 0.6%; Pneumocystis  pneumonia from 
17.0% to 4.4%; toxoplasmosis from 3.4% to 1.4% and tuber-
culosis from 6.4% to 2.6%) [2]. The reduction observed, 
when comparing both periods before HAART to the 
HAART era, evidence the impact of the therapy against HIV 
and the principal opportunistic infections associated.  
  The drugs used as antiretroviral therapy have been classi-
fied in six categories: nucleoside reverse transcriptase inhibi-
tors, nucleotide reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors, cell entry inhibi-
tors (fusion inhibitors and co-receptor inhibitors), integrase 
inhibitors and protease inhibitors (PIs). These compounds 
should be used in drug combination regimens to achieve the 
highest possible benefit, tolerability and compliance and to 
diminish the risk of resistance development [3]. Although   
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the HAART-induced reconstitution of cellular immunity 
seems to be the main determinant in reducing opportunistic 
infections in HIV-positive individuals, clinical and microbio-
logical evidence showed that this class of drugs to be effec-
tive as antitumor, antibacterials, antifungals and anti-
influenza agents [4, 5].  
  Even though, the target of these inhibitors is the HIV-1 
protease, a member of the aspartic protease family [6], the 
preliminary investigations in term of action against oppor-
tunistic parasites, indicate that proteases of some parasites 
could be an unspecific target for HIV-1 PIs. Additionally, 
the results of in vitro and in vivo investigations [7], indicate 
that HIV-1 PIs have a direct effect on some opportunistic 
parasites based on aspartic protease inhibitors [5]. This arti-
cle reviews general pharmacology data of PIs and summarize 
the relevant evidences of their effect against the principal 
opportunistic parasitic infections caused by Plasmodium 
falciparum, Leishmania spp, Toxoplasma gondii and vaginal 
or intestinal protozoan.  
2. HIV-1 PIs 
  There are, at present, 25 compounds which have been 
formally approved by the US Food and Drug Administration 
(FDA) for clinical use in the treatment of the acquired im-
munodeficiency syndrome (AIDS), including 10 PIs (Fig. 1): 
saquinavir1, ritonavir2, indinavir3, nelfinavir4, amprenavir5, 
lopinavir6, fosamprenavir7, atazanavir8, tipranavir9  and 
darunavir10 [3]. PIs are small peptidic or non-peptidic pro-
teins designed to compete for active sites of the protease 
enzyme. Three generation of PIs have been developed with 
the aim to improve the drug efficacy and/or properties such 
as better patient quality of live, increased survival, slowed 
diseases progression, decreased viral load, increased immu-
nological response and decreased opportunist infections [8]. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites  The Open Medicinal Chemistry Journal, 2011, Vol. 5    41 
With the exception of tipranavir (which is based on a cou-
marin scaffold), all these PIs are based on the ‘pepti-
domimetic’ principle, that is they contain a hydroxyethylene 
scaffold which mimics the normal peptide linkage (cleaved 
by the HIV protease) [3]. 
  To date, most treatment guidelines indicate that regimens 
based on lopinavir-ritonavir as the first-line agent, followed 
by fosamprenavir or atazanavir booster with ritonavir or as 
an nonboosted regimen are among the preferred options to 
start HAART [9].  
  Most PIs alone are only moderately absorbed in the gas-
trointestinal tract and their diffusion though anatomical bar-
rier is usually moderate, in part due to high plasma protein 
binding (90-99%), which make PIs concentration lower in 
sanctuary sites such as the genital tract [10,11] and the CNS 
[12] in comparison with plasma. Compared with other PIs, 
 
Fig. (1). Chemical structure of HIV-1 protease inhibitors. 1: Saquinavir; 2: Ritonavir; 3: Indinavir; 4: Nelfinavir; 5: Amprenavir; 6: Lopina-
vir; 7: Fosamprenavir; 8: Atazanavir; 9: Tipranavir; 10: Darunavir. 
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fosamprenavir, lopinavir and darunavir possess better diffu-
sion to sanctuary sites [13,14]. Food contributes to the phar-
macokinetic variability of PIs, but the exact mechanism(s) 
are poorly understood [15]. The first advance was to increase 
the level of existing PIs in the plasma by boosting with rito-
navir [16], which to enhance the effectiveness of PIs treat-
ment by reducing the pill burden, simplifying dosing regi-
mens and improving therapy adherence. Ritonavir coadmin-
istration improves the pharmacokinetic profiles of concomi-
tant PIs, and represents a cornerstone of PI-containing regi-
mens [17].  
  In term of adverse events, PIs show an acceptable safety 
profile. The most common short-term adverse events are 
gastrointestinal order, namely diarrhea [18]. Lipodystrophy 
is a condition associated with long-term exposure to PIs, 
mainly the first-generation compounds. In addition to mor-
phological abnormalities (fat atrophy and fat deposition), 
metabolic disturbances (hyperglycaemia and hyperlipidemia) 
are common [19].  
2.1. First-Generation of PIs 
  The fist PIs was saquinavir (Invirase and Fortovase) 
in 1995, followed in 1996 by the introduction of ritonavir 
(Norvir) and indinavir (Crixivan), in 1997 the nelfinavir 
(Viracept) and in 1999 the amprenavir (Agenerase and 
Prozei) was approved. In terms of evolution of PIs in the 
HAART therapy, these five agents represent the first genera-
tion and at the end of the 1990s were the most widely PIs 
used [8].  
  Saquinavir is a peptidomimetic inhibitor of HIV protease 
with greatly hindered by its nearly complete first pass 
metabolism by cytochrome P450 [20]. The drug inhibits the 
cleavage of the gag-pol protein substrate leading to the re-
lease of structurally defective and functionally inactive viral 
particles. It is active on both HIV-1 and HIV-2, and also has 
activity on chronically infected cells and HIV strains resis-
tant to reverse transcriptase inhibitors. Saquinavir is charac-
terised by a low bioavailability and the metabolism is mainly 
hepatic through cytochrome P450. Resistance has been ob-
served after both in vitro and in vivo drug exposure, with a 
relatively specific mutation profile compared with other pro-
tease inhibitors. Saquinavir is generally well tolerated, with 
mild gastrointestinal symptoms representing the most com-
monly observed adverse effects [21].  
  Ritonavir was protease inhibitors that have revolutionised 
HIV therapy. The extent of oral absorption is high and is not 
affected by food. The drug is primarily metabolised by cyto-
chrome P450 isozymes and, to a lesser extent, by CYP2D6. 
Four major oxidative metabolites have been identified in 
humans, but are unlikely to contribute to the antiviral effect 
[22].  
  Indinavir is a synthetic peptidomimetic competitive in-
hibitor of the HIV aspartyl protease and their major limita-
tion is the drug accumulation and no inductive effect on the 
hepatic CYP enzymes affecting its own metabolism [23]. In 
human urine, seven metabolites of indinavir have been de-
tected and characterized [24]. The main adverse event of 
indinavir is nephrolithiasis, which is a result of the precipita-
tion and crystallization of unmetabolized indinavir monohy-
drate in the renal tubules. Gastrointestinal complaints, as 
well as metabolic alterations, in particular hyperbilirubine-
mia, are among the other most common adverse events 
[23,25]. Significant data have demonstrated that indinavir 
has potent antiretroviral activity, although has pharma-
cologic characteristics that are unfavorable for chronic 
treatment and have been abandoned due to their significantly 
lower efficacy and greater toxicity than others PIs [26]. 
These obstacles have been overcome with the coadministra-
tion of low-dose ritonavir, which significantly improves its 
pharmacokinetic parameters [23]. 
  Nelfinavir is a selective inhibitor of HIV protease, the 
enzyme responsible for post-translational processing of HIV 
propeptides. A unique mutation of the protease gene confers 
resistance. Diarrhoea is the most frequently reported adverse 
event in patients receiving nelfinavir-based combination 
therapy, together with rash, nausea, headache and asthenia 
Nelfinavir is metabolised by the cytochrome P450 system 
[27]. Although less effective than other PIs, nelfinavir is 
positioned as an alternative agent for the treatment of adults 
and adolescents with HIV infection and is an option for those 
unable to tolerate other protease inhibitors, as well as in 
pregnant and paediatric patients with HIV infection, due to 
prolonged viral suppression, good tolerability, a unique re-
sistance profile [28,29]. 
  Amprenavir is a sulfonamide that targets the protease 
enzymes, inhibiting post-transcripcional processing of HIV 
proteins [30]. The antiviral potency of this compounds have 
been demonstrated with various laboratory and clinical HIV 
strain and low toxicity in human cell line expressing T-cell 
markers has been reported [31].  
  The HIV PIs from first generations were combined with a 
backbone of nucleoside analogues, a rapid and durable com-
plete suppression of HIV replication could be obtained for 
the first time in many patients. This virological effect was 
followed by immune recovery and, more importantly by a 
dramatic reduction in the incidence of opportunistic events 
[32]. However, the clinical utility of the first generation of 
PIs was limited by low bioavailability and high pill burdens, 
which ultimately reduced adherence and limited long-term 
viral inhibition [16].  
2.2. Second-Generations of PIs 
  When therapy failure with first generation of PIs occur 
multiple protease resistance mutations were observed, often 
resulting in broad class resistance. To combat PI-resistance 
development, second-generation approaches have been de-
veloped in the early 2000s, including the lopinavir (Aluvi-
ran and Koletra) in 2000 and fosamprenavir (Lexiva 
and Telzir) and atazanavir (Reyataz) in 2003 [16]. Its 
efficacy, tolerability and virological effect had been demon-
strated.  
  Lopinavir is the most widely and lengthily testes PI. The 
drug was specifically designed to overcome the shortcom-
ings of earlier agents in this class. The incidence of gastroin-
testinal disturbances is the main adverse effects together with 
lipid abnormalities [32]. Lopinavir is the only PI coformu-
lated with ritonavir (Kaletra), whose pharmacological 
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clinically effective antiretroviral agent with a high genetic 
barrier to resistance [33]. 
  Fosamprenavir is an inactive, highly water-soluble phos-
phate ester prodrug of amprenavir that contains a sulfona-
mide moiety [34]. This compound was synthesized to allow 
decreased pill burden, which contributes to improved patient 
compliace and it does not have any food restrictions [35]. 
Fosamprenavir is completely hydrolyzed to amprenavir in 
the gut endothelium, which is absorbed and metabolized [8]. 
The drug cause a low resistance and adverse effects com-
pared with others PIs [36].  
  Atazanavir, an azapeptide, shows better metabolic pre-
ofile, fewer drug interaction and improved posology than 
prior PIs. This drug is rapidly absorbed and metabolized by 
the hepatic cytochrome P450 [37]. Atazanavir is generally 
well tolerated with low adverse events, which indirect bilir-
rubin elevation is the most frequent side effects reported 
[37,38].  
2.3. Third-Generation PIs 
  Despite the availability of a growing number of potent 
antiretroviral agents, efforts to completely suppress viral 
replication in patients with HIV-1 infection have been devel-
oped. Recently, a third-generation tipranavir (Aptivus) 
approved in 2005 and darunavir (Prezista) in 2008 received 
full marketing authorisation, which present significantly 
greater potency and genetic barrier for resistance than all 
other PIs [32].  
  Tipranavir is a dihydropyrone and the unique non-
peptidic nature HIV PIs that contains a sulphonamide moiety 
[8]. This compound remain active against most HIV strains 
resistance to others PIs [39] due to their structural flexibility, 
which allows it to fit into the active pocket of the protease 
enzyme in viruses that have become resistant to other PIs 
[40]. Tipranavir appears to have many drug-drug interactions 
and acts as an inhibitor of CYP isoenzymes [8]. 
  The latest PI approved is the darunavir, an oral nonpep-
tidic HIV-1 PI that selectively inhibits the cleavage of HIV 
gag and gag-pol polyproteins, thereby preventing viral matu-
ration. Althougth this compounds has some chemical simi-
larities to amprenavir, it binds approximately 100-times 
more tightly to wild-type Darunavir is highly potent against 
laboratory strains and clinical isolates of wild-type and 
multidrug-resistant HIV and has limited cytotoxicity. The 
drugs did not display cross-resistance with other PIs and is 
primarily metabolized by the hepatic cytochrome P450 en-
zymes. The treatment has been generally well tolerated with 
most events being mild to moderate in severity, including 
diarrhoea, nausea, headache, upper respiratory tract infection 
and nasopharyngitis [41].  
3. ASPARTIC PROTEASES: SOME PRELIMINARY 
EVIDENCES IN OPPORTUNISTIC PROTOZOAN 
PARASITES 
  The proteinases are involved in key areas of the relation 
between infectious agents and host; including antigen pres-
entation, effectors cell function and tissue dissolution and 
remodelling, it is somewhat surprising that the proteinase 
inhibitors of parasite origin have not generally been the sub-
ject of intense research effort [42].  
  Aspartic proteases are a highly conserved family of pro-
teins whose principal characteristic include a bilobal struc-
ture and the use of a catalytic dyad of aspartate residues (one 
in each lobe of the enzyme) to activate a nucleophilic water 
molecule and catalyze peptide cleavage [43]. Aspartic prote-
ases are generally synthesized as zymogens and subse-
quently activated by proteolytic cleavage of the inhibitory 
proregion. They are found in eukaryotes and viruses, and 
have been attributed to a broad range of functions, from nu-
trient degradation to the activation of signaling molecules. A 
number of aspartic proteases have been implicated in viru-
lence, for example, the HIV-.1 protease, the secreted Saps of 
Candida albicans or the hemoglobin degrading proteases of 
parasites ranging from P. falciparum to Schistosoma man-
soni [44]. 
  Aspartic proteases can be divided into a number of fami-
lies. Most aspartic proteases described to date belong to fam-
ily A1, for which the type member is pepsin; the other well-
characterized aspartic protease families are the family A22 
(type member presenilin) and viral family A2 (type member 
HIV-1 protease) [44]. For this last, several inhibitors have 
been designed to mimic endogenous peptides and thereby 
block the active site of aspartyl protease, a retroviral enzyme 
that cleaves the viral gag-pol polyprotein (Fig. 2). Conse-
quently, the drugs prevent the HIV protease from carrying 
out its normal function, which is the proteolytic processing 
of precursor viral proteins into mature viral proteins [3]. In-
trinsic antiviral potency (named as instantaneous inhibitory 
potential) could be greater for these PIs than for other 
antiretroviral drug classes [45]. The basis for this observa-
tion relies on the fact that nucleoside analogues and integrase 
inhibitors target reactions in which a single complex of en-
zyme and viral nucleic acid mediates a key step; by contrast, 
PIs target the whole number of enzymes themselves [32]. 
This action prevents the production of infectious viral parti-
cles with the subsequent decreased of the viral load and the 
partial immune restoration [46]. 
  Protease enzymes seem to play important roles in the life 
cycles of all medically important protozoan parasites and are 
utilized for diverse functions, including the invasion of host 
cells and tissues, the degradation of mediators of the immune 
response and the hydrolysis of host proteins for nutritional 
purposes. Between them, the aspartic proteases play an im-
portant role in physiological and pathology process caused 
by protozoa. Their biochemical and molecular characteriza-
tion have been providing tools to improve our understanding 
of the functions of these enzymes. In addition, studies in 
multiple systems suggest that inhibitors of protozoan prote-
ases have potent antiparasitic effects, which have been dem-
onstrated by some clinically useful drugs [42,47,48]. 
  Within the apicomplexa, has been proposed that there are 
two different families of aspartic proteases with distinct 
evolutionary lineages. The first, more ancient group includes 
certain aspartic proteases of Eimeria tenella (eimepsin), and 
P. falciparum (plasmepsin VI). The second group may have 
been acquired by horizontal transfer and is composed of the 
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plasmepsins I, II, and IV [49]. However a recent study iden-
tified five main groups of apicomplexan aspartic proteases 
using phylogenetic analysis, the best tool which allows the 
classification of the different proteins into evolutionary re-
lated families, that frequently also have related biological 
functions [44]. 
 For  P. falciparum, 10 putative aspartic proteases have 
been described (PfPMI to PfPMX) [50]. The best character-
ized of these are the hemoglobin degradading plasmepsins: 
PfPMI, PfPMIV and histoaspartic protease (HAP). These 
four proteases are expressed during the intraerythrocytic life 
cycle stages and have been localized to the acidic food vacu-
ole, where they are responsible for the first steps in hemo-
globin degradation [51]. 
 For  T. gondii, seven genes coding for putative aspartic 
proteases, identified in the complete genome by homology 
with know human and apicomplexan proteases. TgASP1, 
TgASP3 and TgASP5 genes have been experimentally an-
noted by cDNA sequencing; the other TgASPs were assem-
bled using expressed sequence tag databases and manual 
annotation based on homology [44]. 
  Although there are no report of aspartic proteases in C. 
parvum, Mele et al. 2003 [52] identified several different C. 
parvum sequences that showed homology with this protein 
family when the eimepsin sequence was used as an elec-
tronic probe on the C. parvum genomic database. Addition-
ally, Morales Gomez (2004) [53] also identified several dif-
ferent  C. parvum sequences that showed homology with a 
protein family related to aspartyl proteases. 
  Additional studies in parasites, to identify all the possible 
sequences related with proteases will be needed. The possi-
ble structural relation, similarity in sequences or function 
between these enzymes with the HIV-1 aspartic protease 
could explain the effect of HIV-1 PIs against some opportun-
istic protozoan, even though these last, were formulated with 
unique specificity for HIV-1 aspartic protease. 
4. HIV-1 PIS AS ANTIPROTOZOAN AGENTS 
  The drastic reduction in the incidence, morbidity and 
mortality of AIDS coinfections after the introduction of PIs 
in the antiretroviral therapy was the first line of evidence that 
these compounds could exert a direct effect on opportunistic 
pathogens [54]. Although there are several studies concern-
ing protozoa parasites and HIV co-infection that including 
particularities of its epidemiology, pathogenesis, prophy-
laxis, the direct incidence of treatment on parasite burden 
remain unclear and undefined. In this sense, in vitro and in 
vivo studies have been conducted to recognize the effects of 
HIV-1 PIs against protozoan opportunistic parasites. Even 
though, the studies are scarce, the preliminary evidences 
suggest the unspecific activity of these PIs on some para-
sites. 
  In this article, we review the reports about the antiproto-
zoal activity of PIs. Data was selected from medical litera-
ture published in any language using Medline since 1995 to 
2009 for published literature. Search terms were each PI 
combined with all protozoa parasite with medical impor-
tance. The search strategy yielded a total of 27 articles dur-
ing the last 15 years, including one review article. After ini-
tial screening, nine articles were excluded which did not 
evaluated antiprotozoal activity of PIs (8) or did not pro-
vided the necessary data (1). The data recovered by year of 
publication shown an increase of articles published in the 
last three years (Fig. 3).  
  The analyses indicated that the PIs studied have been 
saquinavir, ritonavir, indinavir, nelfinavir, lopinavir and ata-
zanavir; while no reports were found with amprenavir, 
fosamprenavir, tipranavir and darunavir. The genus of op-
portunistic protozoa involved in the studies have been Plas-
modium, Leishmania, Toxoplasma, Trichomonas, Giardia, 
Cryptosporidium and Microsporidium, which are in correla-
tion with the protozoa that cause major morbidity in HIV 
patients (Table 1).  
4.1. Activity Against Plasmodium spp 
  The World Health Organization estimates that 300-500 
million cases of malaria and 1-2 million deaths due to ma-
laria occur annually [55]. When HIV and malaria parasite are 
present as a coinfection, they enhance each other pathogenic-
ity [56,57]. At the clinical level, the interaction between HIV 
and malarial infection is complex and bidirectional [58]. 
Although the morbidity attributable to each infection in the 
presence of the other is not fully understood, interactions that 
are likely to have significant clinical consequences have 
been described [59, 60]. Interestingly, lines of evidences 
suggest a possible beneficial action of some antiretroviral 
PIs, commonly used in HAART, as antimalarial agents. 
  In this sense, two HIV-1 PIs have been reported to reduce 
in vitro cytoadherence of P. falciparum-infected erythrocytes 
to drug-exposed endothelial cells [61], a process linked in 
vivo with parasite virulence. More recently, Skimer–Adams 
et al, 2004 [62] indicated that three PIs (saquinavir, ritonavir 
and indinavir) directly inhibited the grown of P. falciparum 
in vitro at clinically relevant concentrations, suggesting that, 
some PIs are active against the most virulent human malaria 
parasite, which express a number of aspartic proteases; know 
 
Fig. (2). Mimetic action of hydroxyethylene bond from active 
group of peptidic protease inhibitor with normal peptide linkage 
cleaved by the human immunodeficiency virus protease. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites  The Open Medicinal Chemistry Journal, 2011, Vol. 5    45 
as plasmepsins [51]. This finding was corroborated by 
Parikh et al. (2005) [63] when tested the activity of seven 
HIV-1 PIs against P. falciparum, evidencing that all com-
pounds inhibited the development of parasites at pharmaco-
logically relevant concentrations.  
  Combinations of these antiretroviral PIs in a murine 
model of malaria have been also examined, showing a delay 
in patency and a significant attenuation of parasitemia in 
mice infected with Plasmodium chabaudi and treated orally 
with ritonavir-saquinavir or ritonavir-lopinavir. In addition, 
in vitro enzyme assays demonstrated that P. falciparum 
plasmepsins II and IV are both inhibited by the antiretroviral 
PIs saquinavir, ritonavir and lopinavir [64]. 
  On the other hand, the synergist between HIV-1 PIs and 
antimalarial drugs had been also investigated. A previous 
study suggested that saquinavir and ritonavir behaved syner-
gistically with chloroquine (CQ) against chloroquine-
resistant line in vitro [65]. One year later, He et al. (2008) 
[66], found that all HIV PIs tested were able to enhance the 
antimalarial action of CQ. In both, in vitro and in vivo assays 
systems performed, ritonavir was found to be the most potent 
in patenting the antimalarial action of CQ. More recently, the 
mechanism by which the antiretroviral PIs modulate the CQ 
resistance in malaria parasites was investigated. The authors 
found that CQ-resistant parasites showed increased intracel-
lular glutathione levels in comparison with the CQ-sensitive 
parasites. Treatment with some antiretroviral PIs signifi-
cantly reduced the levels of glutathione (GSH) and glu-
tathione S-transferase activities in CQ-resistant parasites. 
Ritonavir also decreased glutathione reductase activities and 
glutathione peroxidase activities in CQ-resistant parasite 
line. At respect the authors suggest that HIV PIs (ritonavir, 
saquinavir, nelfinavir), especially ritonavir, are able to en-
hance the sensitivity of malaria parasites to CQ by suppres-
sion of GSH levels and alteration of the related enzyme ac-
tivities [67]. 
  Finally, a very recent study indicated that the HIV-PIs 
lopinavir and saquinavir affect preerythrocytic-stage parasite 
development  in vitro. When the effects of HIV-PIs on 
preerythrocytic-stages in vivo were investigated the results 
showed that lopinavir/ritonavir had a dose-dependent effect 
on liver-stage parasite development [68]. 
  Through, the mechanism responsible for the antimalarial 
activity of these antiretroviral PIs is not fully clear, the pre-
liminary data suggesting that select protease inhibitors will 
offer some protection against malaria directly, or potentiat-
ing the antimalarial action of drugs commonly used but with 
reduced efficacy due to the resistance. 
 
Fig. (3). Number of articles about antiprotozoal activity of HIV-protease inhibitors by year (N = 26). 
Table 1.  Studies by HIV-Protease Inhibitor in Relation to their Antiprotozoal Action (01/1995 – 12/2009) 
Protozoos Saquinavir  Ritonavir  Indinavir  Nelfinavir  Lopinavir  Atazanavir 
Plasmodium spp.  8  9  1  2  5  1 
Leishmania spp.  2 1  1  2  1 0 
Toxoplasma gondii  0 1  0  1  0 0 
Trichomonas vaginalis  1 1  0  0  1 0 
Giardia lamblia  1 1  0  0  1 0 
Cryptosporidium parvum  2 2  3  1  0 0 46    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Alfonso and Monzote 
4.2. Activity against Leishmania spp 
  Leishmaniasis is among the most neglected of the tropi-
cal diseases: more than 12 million people are currently in-
fected worldwide, there are 2 million new cases every year 
and 350 million people are considered to be at risk [69].  
  Two basic clinical forms are recognized –cutaneous 
leishmaniasis (CL), a disfiguring and stigmatizing disease, 
and visceral leishmaniasis (VL) or kala azar, which is fatal 
without treatment [69]. Current therapy is suboptimal due to 
toxicity of the available therapeutic agents and drug resis-
tance [70]. In addition, the emergence of AIDS pandemic 
and the occurrence of HIV-Leishmania co-infection are 
added as a new complex problem. 
  Although there are several studies concerning Leishma-
nia/HIV co-infection, some particularities of its epidemiol-
ogy, pathogenesis, prophylaxis and especially of its treat-
ment remain unclear and undefined [69]. With the introduc-
tion of PIs in the antiretroviral therapy for HIV-infected in-
dividuals, the number of co-infected cases reported in Euro-
pean Leishmania-endemic countries fell sharply. Neverthe-
less, the disease is still the third most frequent parasitic op-
portunistic infection in Europe [71]. 
  As far as we know, only three articles have been evalu-
ated the antileishmanial activity of HIV-1 PIs. In 2005, two 
antiretroviral PIs (indinavir and saquinavir), described a 
dose-dependent leishmanicidal activity in vitro, which was 
greater on L. major than on L. infantum promastigotes [72]. 
The authors reported that the inhibition of leishmanial 
growth produced by these compounds may be due to their 
effects on proteasome; which constitute a large, non-
lysosomal, multi-subunit protease complex presents in 
Leishmania, related with the differentiation and replication 
of protozoan [73]. 
  Three years later, Trudei et al. (2008) [74] analyzed the 
efficacy of 3 HIV PIs (nelfinavir, ritonavir and saquinavir) in 
controlling the intracellular growth of Leishmania parasites 
in the human monocytic cell line THP-1 and, more impor-
tantly, in human primary monocyte-derived macrophages 
(MDMs). The results showed that intracellular survival of 
both  L. infantum and  L. donovani markedly reduced after 
treatment with PIs. Interestingly, antileishmanial activity of 
PIs was still seen even when infection was done with a 
Leishmania field isolate that is resistant to sodium stiboglu-
conate (SbV), the drug most commonly used for the treat-
ment of leishmaniasis [74]. 
  Finally, very recently, a very complete study analyzing 
the effect of aspartyl peptidase inhibitors on the L ama-
zonensis proliferation, ultrastructure, interaction with macro-
phages cells and expression of classical peptidases which are 
directly involved in the Leishmania pathogenesis was per-
formed.  
  The results showed that all HIV-1 PIs (lopinavir, nelfi-
navir, amprenavir, indinavir, saquinavir) impaired parasite 
growth in a dose-dependent fashion, especially nelfinavir 
and lopinavir [70]. The authors pointed that the inhibitory 
effect of HIV-1 PIs in vitro were observed at substantial PIs 
concentrations (M range), much higher than those needed 
for HIV peptidase inhibition (on the nM order), probably 
reflecting a much lower affinity of these drugs for a yet uni-
dentified target in Leishmania compared with their affinity 
for HIV peptidase [15]. 
  Interestingly, the research evidenced that HIV-1 PIs 
treatment caused profound changes in the Leishmania ultra-
structure, such as cytoplasm shrinking, a higher number of 
vesicles, nucleus surrounded by endoplasmic reticulum, mi-
tochondrial swelling and myelin-like structures, blocks of 
condensed chromatin [70]. These changes were dependent of 
the PIs (nelfinavir or lopinavir) used or its combination. In 
addition, the hydrolysis of HIV peptidase substrate by L. 
amazonensis extract was inhibited by pepstatin and HIV PIs, 
suggesting that an aspartyl peptidase may be the intracellular 
target of the inhibitors. Nevertheless, despite these beneficial 
effects, the HIV PIs induced an increase in the expression of 
cysteine peptidase b (cpb) and the metallopeptidase gp63 
[70], two well-known virulence factors expressed by 
Leishmania spp [75,76]. At respect future studies should be 
needed to understand and to define if the use of HIV-1 PIs 
could be beneficial or not in the treatment of leishmaniasis.   
4.3. Activity Against T. gondii 
 T.  gondii is a widely distributed apicomplexan parasite of 
great medical importance. Most primary infections are as-
ymptomatic, and may exist in up to one-third of the human 
population worldwide [77]. In immunocompromised pa-
tients, especially those with AIDS, reactivation of latent in-
fection causes necrotic lesions producing life threatening 
encephalitis [78]. The majority of these cases are thought to 
result from recurrence of chronic infections, due to the de-
crease in cellular immunity [79]. 
  Until present, Toxoplasmic encephalitis (TE) still repre-
sents the most common cerebral mass lesion in patients in-
fected with HIV. However, of the five longitudinal studies 
that have estimated the occurrence of TE, both before 
HAART and since its introduction, four have reported that 
the use of HAART in which PIs were included has resulted 
in marked decreases in TE among HIV positive individuals 
[54].  
  Preliminary evidences showing direct pharmacological 
effect on T. gondii growth using ritonavir and nelfinavir [7] 
were reported. These PIs were highly inhibitory for 
Toxoplasma growth, with concentrations that can be ar-
chived in humans [15]. Interestingly, none of the PIs tested 
in this research affected the anti-Toxoplasma activity of 
pyrimethamine or sulfadiazine in vitro, the first line of anti-
Toxoplasma drugs. 
  The mode of action of HIV-1 PIs on T. gondii remains to 
be elucidated and future studied defining the mechanism 
involved in the inhibition of T. gondii growth by PIs could 
allow define the specificity of HIV-1 PIs against another 
protozoan parasites proteases. 
4.4. Activity Against Giardia and Trichomonas vaginalis 
 Trichomonas  vaginalis  is an important protozoan parasite 
transmitted principally through vaginal intercourse. Despite 
a relative paucity of studies of the prevalence and incidence 
of trichomoniasis, recent publications suggest that T. vagi-HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites  The Open Medicinal Chemistry Journal, 2011, Vol. 5    47 
nalis is one of the most common sexually transmitted infec-
tions worldwide with over 170 million cases per year 
[80,81]. It is now recognized that Trichomonas may play a 
critical and underrecognized role in amplifying HIV trans-
mission, and it may have a major impact on the epidemic 
dynamics of HIV in African-American communities. 
  In the context of giardiasis, the acute stage, posterior to 
infection with this parasite can last from 3 to 4 days, but can 
persist for much longer. Persistent infection and diarrhea 
may occur in immunocompromised individuals, for example 
IgA deficiency, but is less obvious in cases of HIV individu-
als [82] 
  Metronidazole is the drug of choice to treat both medi-
cally important parasites although resistance, particularly in 
T. vaginalis is of great concern [83]. For giardiasis, even 
though, there are alternatives to metronidazole, treatment 
failures with all commonly used drugs are well documented 
[84]. 
  The use of PIs could allow a better clinical management 
in T. vaginalis or Giardia spp infections. Nevertheless, the 
possible utility of these inhibitors is practically unexplored. 
As far as we know; only one study had been investigated the 
in vitro activity of Kaletra (co-formulation of lopinavir and 
ritonavir), ritonavir and saquinavir against G. duodenalis and 
T. vaginalis. Kaletra was the most effective overall, with 
50% effective. Within the range of human plasma concentra-
tion for ritonavir, only G. duodenalis was inhibited. Lopi-
navir alone was less inhibitory than ritonavir but was associ-
ated with a blockage in cytoquinesis of G. duodenalis tro-
phozoites. Additionally, saquinavir was not effective against 
these protozoans [85].  
  Further investigations, confirming beneficial effects of 
HIV-1 PIs against T. vaginalis and G. duodenalis are essen-
tials. The elucidation of possible targets for the HIV-PIs in 
these parasites could be essential to develop new drugs to 
protect against infection by both parasites.  
4.5. Activity Against Cryptosporidium,  Microsporidium 
and Isospora Belli  
  Infection with the apicomplexan parasite Cryptosporid-
ium parvum leads to self-limiting diarrhoea in immunocom-
petent individual, but can develop into a severe and chronic 
disease in immunocompromised patients [86]. With the in-
troduction of PIs as part of the HAART in the treatment of 
HIV infections, a beneficial effect was noted in AIDS pa-
tients suffering from cryptosporidiosis [87,88]. At respect it 
has been hypothesised that protease inhibitors (PI) could 
play a chemotherapeutic role in controlling cryptosporidio-
sis, given that protease activity has been observed during 
several of the developmental stages of C. parvum and that 
the proteases of C. parvum are believed to be essential for 
the host cells to become infected [89-92]. However, direct 
antiparasitic effects of antiretroviral PIs on C. parvum have 
not been sufficiently explored, as for the most of protozoan 
opportunistic parasites. Even though it has been concluded 
that the effect of these antiretroviral PIs on infections with C. 
parvum is secondary following immunological restoration 
[87] and none aspartyl protease have been described func-
tionally in C. parvum several different C. parvum sequences 
that showed homology with a protein family related to aspar-
tyl proteases were previously described [52,53]. Future stud-
ies could to link these proteins as possible targets for HIV PIs.  
  Preliminarily a recent study showing that indinavir di-
rectly interferes with the cycle of C. parvum, was reported 
and a marked reduction in oocyst shedding and in the num-
ber of intracellular parasites was observed [52]. In the same 
year, the effect of five PIs used in HAART on the excysta-
tion, invasion and development of this parasite in a cell cul-
ture system were tested. The results showed that indinavir, 
nelfinavir and ritonavir inhibited parasite development sig-
nificantly. The inhibitory effect was increased when the 
aminoglycoside paromomycin was combined with the PIs 
indinavir, ritonavir, and to a lesser extent saquinavir, com-
pared to the PIs alone [86]. 
  More recently, Human ileocecal adenocarcinoma tumor 
cells (HCT-8) were used as in vitro model to evaluate the 
activity of indinavir on C. parvum. The results demonstrated 
that PIs directly exert an inhibitory effect on this parasite and 
the extent of this effect depended on the specific dose and 
the duration of treatment. In addition several different C. 
parvum sequences that showed homology with a protein 
family related to aspartyl proteases were identified [53]. At 
respect, the authors pointed that although there are no reports 
of aspartyl proteases in C. parvum, the inhibitory effect of 
PIs on C. parvum growth in vitro suggests that aspartyl pro-
teases could have some important functions for this parasite. 
In fact, proteolytic activities have been demonstrated during 
peak periods of excystation in C. parvum oocysts and cys-
teine and serine protease classes have been functionally as-
sociated with this process [53].  
 For  Microsporidium and Isospora belli, until now, none 
assay detecting the possible effect of HIV-1 PIs on this para-
site has been performed. The identification of in vitro and in 
vivo activities of these inhibitors, in combination with the 
study of the aspartic proteases enzymes for both parasites 
could contribute to find clinical and microbiological interest-
ing findings.  
5. CONCLUSIONS 
  The introduction of the PIs as part of the HAART in the 
treatment of HIV-infections has been evidenced an impact in 
the AIDS disease evolution and the outcome of opportunistic 
infections. Although, other formulations are included in the 
HAART, and the final effect of the treatment is based on the 
combination of all the inhibitors (proteases and transcriptase 
inverse), the possible effects of PIs against other opportunis-
tic pathogens, indicate their efficacy and multiplicity of 
functions. The HIV antiretroviral PIs were developed with 
unique specificity for the HIV-1 aspartyl protease, but could 
be possible their specificity for another parasitic proteases. 
In addition, even though this possibility could be reasonable, 
unrelated effects of HIV PIs on some protozoan should be 
considered. Additional studies should be needed to provide 
valuable information on ultrastructural modifications and 
toxic effect on the cells exposed to these PIs. The sustrate –
inhibitors specificity studies are crucial to define the specific 
mechanism for the inhibition of other proteases, even though 
these PIs were formulated with unique specificity.  48    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Alfonso and Monzote 
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